REDHILL BIOPHARMA LTD
NASDAQ: RDHL (Redhill Biopharma Ltd.)
Last update: yesterday, 4:58AM1.43
0.20 (16.54%)
| Previous Close | 1.23 |
| Open | 1.23 |
| Volume | 124,571 |
| Avg. Volume (3M) | 499,237 |
| Market Cap | 3,290,370 |
| Price / Earnings (Forward) | 1.43 |
| Price / Sales | 0.190 |
| Price / Book | 203.21 |
| 52 Weeks Range | |
| Earnings Date | 10 Apr 2025 |
| Profit Margin | -102.80% |
| Operating Margin (TTM) | -69.57% |
| Quarterly Revenue Growth (YOY) | 382.00% |
| Total Debt/Equity (MRQ) | 914.75% |
| Current Ratio (MRQ) | 0.540 |
| Operating Cash Flow (TTM) | -9.37 M |
| Levered Free Cash Flow (TTM) | -5.39 M |
| Return on Assets (TTM) | -37.28% |
| Return on Equity (TTM) | -1,708.61% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | Redhill Biopharma Ltd. | - | - |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.13 |
|
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Institutions | 4.30% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Federation Des Caisses Desjardins Du Quebec | 30 Jun 2025 | 3,388 |
| Gamma Investing Llc | 30 Jun 2025 | 2,061 |
| Financial Management Professionals, Inc. | 30 Jun 2025 | 9 |
| Vermillion Wealth Management, Inc. | 30 Jun 2025 | 2 |
| Date | Type | Details |
|---|---|---|
| 05 Sep 2025 | Announcement | RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights |
| 20 Aug 2025 | Announcement | RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win |
| 18 Aug 2025 | Announcement | RedHill Received Talicia® Licensing Payments Totaling $1.1 Million |
| 21 Jul 2025 | Announcement | RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease |
| 01 Jul 2025 | Announcement | RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |